Navigation Links
Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
Date:4/21/2010

High Shear Processing Leader Unveils Controlled, Scalable Approach at INTERPHEX 2010 (April 20-22, NYC)

Newton, MA (PRWEB) April 21, 2010 -- At INTERPHEX 2010 (April 20-22, NYC), Microfluidics International Corporation (OTCBB: MFLU), the gold standard in pharmaceutical nanomaterials processing, will introduce Microfluidics Reaction Technology™ (MRT) as a cutting-edge platform for continuous pharmaceutical manufacturing. Combining a unique high shear fluid processor with expert process development, MRT is a revolutionary technology for bottom-up nanoparticle creation:

 
  • Continuous crystallization for production of highly crystalline drug nanoparticles
  • Multiphase chemical reactions
  • Nanoencapsulation of actives
  • Process intensification

MRT enables companies to transform their manufacturing processes from batch to continuous in order to drastically reduce the time and cost of commercial drug production. By creating nanoparticles bottom-up and controlling their growth, MRT allows research teams to create stable and consistent nanoemulsions, for example, at previously unattainable sizes and narrow distributions (e.g. Azithromycin with a z-average particle size of 82 nm).

Microfluidics will describe the technology in greater detail at its press conference on Wednesday, April 21, 8:30 AM, at INTERPHEX 2010, Jacob K. Javits Convention Center in New York City. POWREX Corporation, the exclusive distributor of Microfluidics technology in Japan, will also speak at the press event on bringing MRT to Asia.

“According to an independent 2010 survey that we commissioned, 80 percent of pharmaceutical companies plan to invest in continuous crystallization technology,” said Michael C. Ferrara, President and CEO of Microfluidics. “MRT is the technology they are seeking. It has the potential to revolutionize pharmaceutical production by serving as a scalable platform for continuous manufacturing and by enabling pharma companies to make purer, more consistent drugs faster with improved stability and bioavailability.”

The technology has immediate value in the pharmaceutical, biotechnology and energy industries. Some of the applications ideal for MRT include more effective and tailored drugs, more efficient catalysts for fuel cells, and nanomaterials for batteries, photovoltaics and supercapacitors.

"MRT allows companies to improve bioavailability, target delivery and encapsulate actives more efficiently than any top-down process or traditional crystallization method," said Thomai “Mimi” Panagiotou, PhD., Microfluidics Chief Technology Officer. “Currently, the typical batch crystallization process involves several steps, often in locations across the country, which can take weeks. MRT simplifies the process and has been proven to reduce production time to a matter of hours. Its innovative capabilities for continuous crystallization and chemical reactions have the potential to transform the manufacture of drugs and chemicals by significantly streamlining the steps, timing and cost of consistent, continuous large-scale commercial production.”

To learn more about MRT attend the Microfluidics INTERPHEX press conference, visit the company’s Interphex Booth #2214 or contact Kris Sarajian at ksarajian(at)mfics(dot)com or (+1) 617.969.5452 x233.

ABOUT MICROFLUIDICS
Microfluidics (OTCBB: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company’s headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.
By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit www.microfluidicscorp.com.

Contact:
Kris Sarajian
Microfluidics International Corporation
617-9695452 ext. 233
ksarajian(at)mfics(dot)com

Editorial Contact:
Barbara Rudolph   
Rudolph Communications, LLC
781-229-1811
bjr(at)rudolphcommunications(dot)com

# # #

Read the full story at http://www.prweb.com/releases/nanotechmanufacturing/nanotechnology/prweb3888574.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Marriage of microfluidics and optics could advance lab-on-a-chip devices
2. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
3. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
4. Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009
5. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
6. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
7. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
8. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
9. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
10. GEN Reports on Growing Reliance on Microfluidics Technology
11. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing 
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)... Mass. , March 1, 2017  Aware, Inc. ... services, announced that Richard P. Moberg has ... and co-President and Chief Financial Officer and Treasurer of ... continue to serve as a member of the Board ... Russell , Aware,s co-Chief Executive Officer and co-President, General ...
Breaking Biology News(10 mins):